FAKTOR OPTIONSSCHEIN - AMGEN | Real-time BOERSE MUENCHEN 07:45:40 2024-07-12 am EDT | ||
| 7.09 EUR | -0.70% |
|
| Current month | -9.04% | ||
| 1 month | -15.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 7.09 | -0.70% |
| 24-07-11 | 7.14 | -3.12% |
| 24-07-10 | 7.37 | -4.04% |
| 24-07-09 | 7.68 | -1.79% |
| 24-07-08 | 7.82 | -0.38% |
Real-time BOERSE MUENCHEN
Last update July 12, 2024 at 07:45 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD2VEE |
| ISIN | DE000HD2VEE3 |
| Date issued | 2024-02-21 |
| Strike | 487.7 $ |
| Maturity | Unlimited |
| Parity | 21.43 : 1 |
| Emission price | 10.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.99 € |
|---|---|
| Lowest since issue | 7.08 € |
| Spread | 0.01 € |
| Spread % | 0.14% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
325.1
USD
Average target price
316.1
USD
Spread / Average Target
-2.75%
- Stock Market
- Certificates
- Certificat
